
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
GeneCentric was founded based on intellectual property from Drs. Neil Hayes and Chuck Perous laboratories at the Lineberger Comprehensive Cancer Center at the UNC School of Medicine. GeneCentric currently has two unique platform technologies: The Lung Subtype Platform (LSPTM) stratifies lung cancer patients into subtypes, which are important for appropriate therapeutic selection. The first application of LSPTM was licensed to and independently developed by Laboratory Corporation of America Holdings (LabCorp) and is now available through its specialty testing business, Integrated Oncology, as HistoPlusSM: Lung Cancer. GeneCentrics second platform technology is the Hypoxia Signature which has the potential to identify patients...
Lung cancer diagnostics and hypoxia signature
Genecentric therapeutics, inc operates in the Biotechnology research industry.
Genecentric therapeutics, inc's revenue is 11m - 100m
Genecentric therapeutics, inc has 11 - 50 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.